...
首页> 外文期刊>Human Molecular Genetics >Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).
【24h】

Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).

机译:家族性肾细胞癌相关的t(2; 3)(q35; q21)破坏了新型MFS转运蛋白基因DIRC2。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Previously, we described a family with a significantly increased predisposition for renal cell cancer co-segregating with a t(2;3)(q35;q21) chromosomal translocation. Several primary tumors of the clear cell type from different family members were analyzed at a molecular level. Loss of the derivative chromosome 3 was consistently found. In addition, different somatic Von Hippel Lindau (VHL) gene mutations were observed in most of the tumors analyzed, even within the same patient. Based on these results a multistep tumorigenesis model was proposed in which (non-disjunctional) loss of the derivative chromosome 3 represents an early event and somatic mutation of the VHL gene represents a late event related to tumor progression. More recently, however, we noted that these two anomalies were absent in at least one early-stage tumor sample that we tested. Similar results were obtained in another family with renal cell cancer and t(3;6)(q12;q15), thus suggesting that another genetic event may precede these two oncogenetic steps. We speculate that deregulation of a gene(s) located at or near the translocation breakpoint may act as such. In order to identify such genes, a detailed physical map encompassing the 3q21 breakpoint region was constructed. Through a subsequent positional cloning effort we found that this breakpoint targets a hitherto unidentified gene, designated DIRC2 (disrupted in renal cancer 2). Computer predictions of the putative DIRC2 protein showed significant homology to different members of the major facilitator superfamily (MFS) of transporters. Based on additional DIRC2 expression and mutation analyses, we propose that the observed gene disruption may result in haplo-insufficiency and, through this mechanism, in the onset of tumor growth.
机译:以前,我们描述了一个家族,其肾脏细胞癌的易感性与t(2; 3)(q35; q21)染色体易位共分离。在分子水平上分析了来自不同家族成员的几种透明细胞类型的原发性肿瘤。一致地发现衍生染色体3的丢失。此外,在大多数分析的肿瘤中,甚至在同一患者中,也观察到了不同的体细胞冯·希佩尔·林道(VHL)基因突变。基于这些结果,提出了多步肿瘤发生模型,其中衍生染色体3的(非分离的)丢失代表早期事件,而VHL基因的体细胞突变代表与肿瘤进展有关的晚期事件。但是,最近,我们注意到在我们测试的至少一个早期肿瘤样本中不存在这两个异常现象。在另一个患有肾细胞癌和t(3; 6)(q12; q15)的家庭中获得了类似的结果,因此表明在这两个致癌步骤之前可能还有另一个遗传事件。我们推测,位于易位断点处或附近的基因的失调可能是这样。为了鉴定此类基因,构建了包含3q21断点区域的详细物理图谱。通过随后的位置克隆工作,我们发现该断点靶向迄今尚未鉴定的基因,称为DIRC2(在肾癌2中被破坏)。推定的DIRC2蛋白的计算机预测显示与转运蛋白主要促进子超家族(MFS)的不同成员具有显着同源性。基于其他DIRC2表达和突变分析,我们建议观察到的基因破坏可能导致单倍功能不足,并通过这种机制导致肿瘤生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号